Recent Alimera Data Featured in Scientific Programming at Upcoming Annual Congress

Rhea-AI Summary

Alimera Sciences announced the presentation of ILUVIEN® PALADIN data at the upcoming ARVO conference in Denver, Colorado from May 1-4, 2022. Key highlights will include a presentation on May 2 regarding three-year outcomes from the PALADIN Phase IV Study, assessing the predictive value of prior steroid challenge. Additionally, poster sessions will cover the distribution of intraocular pressure outcomes and the safety and effectiveness of the fluocinolone acetonide intravitreal implant from the European IRISS registry study. These studies aim to confirm ILUVIEN's benefits for patients with diabetic macular edema.

Positive

• Presentation of positive clinical data at a major ophthalmology conference, potentially increasing visibility and interest in ILUVIEN.
• Positive outcomes from the PALADIN Phase IV Study may strengthen ILUVIEN's market position.

Negative

• None.

Follow up ILUVIEN® PALADIN data to be presented onsite at the annual Association for Research in Vision and Ophthalmology (ARVO) conference

ATLANTA, April 28, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced today that ILUVIEN^® will be highlighted in various scientific abstracts at the annual Association for Research in Vision and Ophthalmology (ARVO) conference being held in Denver, Colorado from May 1-4 and virtually May 11-12, 2022.

Key ILUVIEN Abstracts:

Presentation

• Monday, May 2 11:51am - 12:08pm CDT – Chris Fuller, MD, Three Year Outcomes from the PALADIN Phase IV Study: Predictive Value of Prior Steroid Challenge and Intraocular Pressure Outcomes

Posters

• David Dyer, MD, Three Year Outcomes from the PALADIN Phase IV Study: Distribution of Intraocular Pressure Outcomes by Patient Subgroup
• Ramin Khoramnia, MD, Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): Final study results from the European IRISS registry study.

ARVO is among the largest vision research meetings held annually in the field of ophthalmology. Annual meeting educational content is planned by the ARVO program committee, and ARVO does not endorse, promote, approve or recommend the use of any products, devices or services.

About PALADIN
The PALADIN study was a phase 4, open-label, prospective, observational study conducted over 36 months at 41 sites across the United States. This study was designed and developed to confirm the benefit of using a prior course of corticosteroid as indicated in the ILUVIEN U.S. label, to mitigate the risk of uncontrolled IOP elevation. Researchers enrolled 202 eyes in 159 patients with DME who had previously received corticosteroid treatment without a clinically significant rise in IOP. All eyes were treated with ILUVIEN and patients were followed for up to 36 months. Additionally, secondary outcomes confirmed improvement in vision and reduction in treatment burden and retinal thickness variability.

About IRISS
The IRISS study was a phase 4 study designed to assess the long-term safety and effectiveness of the fluocinolone acetonide (FAc) implant in all indications in real-world practices in Europe. Six-hundred-and-ninety-five eyes from 556 patients were treated with the FAc implant. Patients receiving FAc implants between 2013 and 2017 were included and monitored until the last patient reached ≥3 years of follow-up. Study included data collected prospectively and retrospectively (51.6% and 48.4%, respectively). Other outcomes included mean intraocular pressure data over time, IOP events, use of IOP-lowering therapy, mean change in visual acuity, and supplemental therapy use among others.

About Alimera
Alimera is a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com.

For press inquiries: Cassy Dump for Alimera 619-971-1887 cassy.dump@precisionvh.com

For investor inquiries: Scott Gordon for Alimera scottg@coreir.com

FAQ

When will the ILUVIEN PALADIN data be presented?

The ILUVIEN PALADIN data will be presented at the ARVO conference from May 1-4, 2022.

What key topics will be discussed regarding ILUVIEN at the ARVO conference?

Key topics include three-year outcomes from the PALADIN Phase IV Study and results from the European IRISS registry study.

What is the stock symbol for Alimera Sciences?

The stock symbol for Alimera Sciences is ALIM.

What is the purpose of the PALADIN study?

The PALADIN study aims to confirm the benefits of ILUVIEN in patients with diabetic macular edema who have previously received corticosteroid treatment.